S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

$5.02
-0.31 (-5.82%)
(As of 04/12/2024 08:51 PM ET)

Autolus Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 5 Analyst Ratings

Analysts' Consensus Price Target

$8.16
62.55% Upside
High Forecast$11.00
Average Forecast$8.16
Low Forecast$4.80
TypeCurrent Forecast
4/16/23 to 4/15/24
1 Month Ago
3/17/23 to 3/16/24
3 Months Ago
1/16/23 to 1/16/24
1 Year Ago
4/16/22 to 4/16/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
6 Buy rating(s)
7 Buy rating(s)
5 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$8.16$7.30$7.69$8.60
Predicted Upside62.55% Upside105.78% Upside149.36% Upside324.48% Upside
Get Autolus Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter.

AUTL Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AUTL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Autolus Therapeutics Stock vs. The Competition

TypeAutolus TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.68
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside62.55% Upside767.52% Upside10.21% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/12/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$9.00+68.86%
4/9/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$10.00 ➝ $11.00+102.58%
12/13/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$3.20 ➝ $4.80+1.48%
11/15/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
11/9/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$10.00+170.27%
5/5/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$8.00 ➝ $6.00+212.50%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 05:30 AM ET.

AUTL Price Target - Frequently Asked Questions

What is Autolus Therapeutics's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for Autolus Therapeutics stock is Moderate Buy based on the current 1 hold rating and 4 buy ratings for AUTL. The average twelve-month price prediction for Autolus Therapeutics is $8.16 with a high price target of $11.00 and a low price target of $4.80. Learn more on AUTL's analyst rating history.

Do Wall Street analysts like Autolus Therapeutics more than its competitors?

Analysts like Autolus Therapeutics more than other Medical companies. The consensus rating score for Autolus Therapeutics is 2.80 while the average consensus rating score for medical companies is 2.68. Learn more on how AUTL compares to other companies.

Does Autolus Therapeutics's stock price have much upside?

According to analysts, Autolus Therapeutics's stock has a predicted upside of 82.23% based on their 12-month stock forecasts.

What analysts cover Autolus Therapeutics?

Autolus Therapeutics has been rated by Needham & Company LLC, and Truist Financial in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:AUTL) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners